High-Grade Endometrioid Endometrial Cancers Likely to Benefit from ImmunotherapyCuretoday.comPatients with high-grade endometrioid endometrial cancer may benefit from immunotherapy treatment compared with women with lower-grade disease, according to st… Continue reading
High-Grade Endometrioid Endometrial Cancers Likely to Benefit from ImmunotherapyCuretoday.comPatients with high-grade endometrioid endometrial cancer may benefit from immunotherapy treatment compared with women with lower-grade disease, according to st… Continue reading
OncLiveDr. Roussos Torres on the Potential for Immunotherapy in HER2+ Breast CancerOncLiveEvanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients wit… Continue reading
OncLiveDr. Roussos Torres on the Potential for Immunotherapy in HER2+ Breast CancerOncLiveEvanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients wit… Continue reading
Medical XpressStem cells from adults function just as well as those from embryosMedical XpressDonor age does not appear to influence the functionality of stem cells derived from adult body tissues, concludes a new review. The analysis of research on in… Continue reading
Washington University School of Medicine in St. LouisExperimental arthritis drug prevents stem cell transplant complicationWashington University School of Medicine in St. LouisAn investigational drug in clinical trials for rheumatoid arthritis prevents… Continue reading
Cornell Chronicle |
Mammary stem cells challenge costly bovine disease
Cornell Chronicle Mastitis is the most expensive disease in the dairy industry. Each clinical case can cost a dairy farmer more than $400 and damages both the cow’s future output as well as her comfort. Bovine mastitis is typically treated with antibiotics, but with the … |
Benzinga |
Chardan’s Top Pick For 2018: Gene Therapy Firm Uniqure
Benzinga Amusa expects uniQure, with a scaled manufacturing process, to beat Spark Therapeutics Inc (NASDAQ: ONCE) to market with its AAV-based hemophilia B gene therapy. Hemophilia B presents a market opportunity north of $15 billion, and Amusa anticipates a … |